...and $2 million in Entest shares. Thomas Ichim, CEO of Medistem, will become CSO of Entest...
...in 4Q10. Entest is a subsidiary of Bio-Matrix Scientific Group Inc. (OTCBB:BMSN, San Diego, Calif.) Entest BioMedical Inc....

...earlier this year to develop an immunotherapeutic vaccine for cancer. Further terms were not disclosed. Entest...
...diabetes screening products and is developing adipose-derived stem cells to treat traumatic brain injury (TBI). Entest...
...a subsidiary of Bio-Matrix Scientific Group Inc. (OTCBB:BMSN, San Diego, Calif.) (see BioCentury, Aug. 17). Entest BioMedical Inc....

...Bio-Matrix plans to spin out its subsidiary Entest Biomedical Inc. into a public company, which will focus on...
...by Entest, is conducting pilot testing of the newco's undisclosed lead diagnostic for gestational diabetes. Entest...